Search Results for “cancer” – Page 143 – media

AI to Replace Doctors and Nurses for Tasks

University College London Hospital (UCLH) and the Alan Turing Institute are working together on Artificial Intelligence to carry out works which are traditionally done by the doctors and nurses; from deciding which accidental and emergency patients to be consulted first to diagnosing cancer on CT scan.
- Source: Ddu
- 758
- May 23, 2018
AI digital health New Approvals
Study Shows Cytokines Worsens Lupus

A research study led by Professor Marina Botto, from the Department of Medicine in Imperial College London, revealed that a particular component of the immune system called C1q triggers an alarm when the body is attacked by a bacteria or virus and helps in coordinating the defense.
- Source: Ddu
- 450
- May 23, 2018
lupus Researches
Click-To-Release Chemotherapy – A Novel Approach

Tagworks Pharmaceuticals, based at Radboud University Medical Center, have developed a novel technique for the targeted delivery of ADCs to treat tumors. By the controlled 'click-to-release' of the chemotherapy drug from its tumor-binding carrier, the treatment would reach the right location.
- Source: Ddu
- 491
- May 23, 2018
cancer Researches
Fatty Liver Disease – Intestinal Microbiota Might Be the Cure

A research team at Tufts University revealed that good microbes in gastrointestinal tract could prevent liver inflammation, the major symptom of NAFLD. When the research was conducted on a mice model, they identified two key metabolites produced by the bacteria namely I3A and TA, which could ultimately reduce the severity of NAFLD.
- Source: Ddu
- 553
- May 23, 2018
liver disease Researches
Accent raised $40 Million to Develop Epitranscriptomics Studies

Cambridge, Mass.-based Biotech startup Accent Therapeutics announced $40 million A series funding to develop cancer treatment based on epitranscriptomics, an RNA-modifying protein (RMPs) which have been connected to recent cancer studies.
- Source: Ddu
- 654
- May 21, 2018
biotech cancer Company Insight DNA
AbbVie pressurized to keep low price for Imbruvica formula

This year AbbVie launched Imbruvica, a single tablet for blood cancer treatment. It has been designed as a convenient therapy measure for patients who used the old tablets as often as four times a day. Adapting the new single tablet in their treatment regimens will prove to be an expensive proposition for some patients as the new tablet comes with a price tag of $400 each, triple the cost of the older tablets.
- Source: Ddu
- 1,099
- May 17, 2018
AbbVie Company Insight pharma pharmaceutical
Breakdown of Pharma Events Since 2017

As a new, erratic administration consolidated its position in the White House and firmed its foundations in the federal government, 2017 turned out to be uncertain for the biopharma industry. Then President-elect Donald Trump saying that the industry was getting away with murder on pricing did not bode well for the industry but more than a year later after the President assuming office, real reform has been spared for biopharma.
- Source: Ddu
- 648
- May 17, 2018
global pharma influencers Market Views pharma
Feds join lawsuits claiming Insys used strip club visits, super-doses and more to boost Subsys sales

Prosecutors have already charged Insys founder John Kapoor and won guilty pleas from two characters in an ongoing kickbacks probe. Now, the Justice Department has escalated the case by joining in with whistleblowers who've detailed a stunning range of techniques the company allegedly used to push its powerful opioid painkiller.
- Source: FiercePharma
- 642
- May 16, 2018
Company Insight lawsuit pharma
Amsterdam airport to be a new site for EU CAR-T manufacturing facility of Gilead

When it comes to manufacturing CAR T drugs (personalized treatments engineering immune cells to destroy cancer cells of patients) speed is of utmost importance. A new manufacturing site has been decided upon by Gilead for Yescarta, its CAR-T therapy at a Netherlands airport.
- Source: drugdu
- 661
- May 16, 2018
cancer CAR T-cells FDA New Approvals
Biotechnology Company Abpro postpones $69M IPO

According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
- Source: Ddu
- 593
- May 14, 2018
biotech Company Insights IPO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.